XLO vs ANVS Comparison

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.

Annovis Bio Inc is a late-stage clinical drug platform company addressing neurodegeneration, including Alzheimer's disease (AD) and Parkinson's disease (PD). The Company is developing its product candidate, buntanetap, a synthetically produced, orally administered, brain-penetrant small molecule designed to treat AD, PD, and potentially other chronic neurodegenerative diseases by inhibiting the synthesis of neurotoxic proteins and TDP43, which contribute to neurodegeneration and reduced axonal transport. Its pipeline includes buntanetap for chronic neurodegeneration, including AD, PD, and PDD, as well as in certain combination therapies, ANVS405 for acute neurodegeneration, and ANVS301 for AD.